Free Trial
NASDAQ:TENX

Tenax Therapeutics Q1 2026 Earnings Report

Tenax Therapeutics logo
$12.42 -0.08 (-0.60%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Tenax Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Tenax Therapeutics Earnings Headlines

SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.

View Tenax Therapeutics Profile